Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review

Abstract

ObjectivesTo summarise real-world data from studies reporting golimumab persistence in European immune-mediated rheumatic disease (IMRD) populations and to report pooled estimates.DesignSystematic literature review.Data sourcesRelevant literature was identified through searching Medline and Embase via Ovid as well as the conference databases of European League Against Rheumatism and American College of Rheumatology—Association of Rheumatology Health Professionals.Eligibility criteriaWe screened records using predefined patients, interventions, comparators, outcomes and study design criteria. Eligible studies included reports of persistence among adult IMRD patients in Europe receiving treatment with subcutaneous golimumab. Clinical trials, randomised controlled trials, literature reviews, editorials, guidelines and studies with <20 patients receiving golimumab were excluded.Data extraction and synthesisFollowing double screening by two independent reviewers, 27 studies out of 578 identified records were selected for inclusion and subsequent data extraction. Persistence was most commonly reported at 12and 24 months; hence, pooled persistence estimates were calculated for these two time points and reported according to indication.ResultsPersistence ranged between 58.1% (psoriatic arthritis (PsA) patients regardless of treatment line) and 75.7% (biological-naïve rheumatoid arthritis patients) at 12 months; at 24 months, the range was 43% (axial spondyloarthritis (AxSpA) patients regardless of treatment line) and 69.6% (biological-naïve PsA patients). On the basis of data from 12 studies, persistence with golimumab treatment was either significantly higher or not significantly different from other tumour necrosis factor inhibitors (TNFi).ConclusionsGolimumab persistence at 24 months approximates 50%, with a lower persistence among AxSpA (43%) patients. However, as the number of studies in these populations was low, they warrant further research. In 12 studies comparing various TNFi treatments, golimumab was shown to have significantly better or equal persistence to its comparators.

Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany

“…This notion is supported by the analyses demonstrating a cost-effectiveness of golimumab therapy among patients with PsA and AS [18,19]. Furthermore, a recent systematic review of 12 studies showed that patients treated with golimumab had higher persistence when compared with other anti-TNF treatments, especially in RA and PsA setting [20]. Therefore, use of golimumab might reduce HCRU also due to a high long-term persistence among the patients with rheumatic diseases using this medication.…”

Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis

“…Compared to SEC, multiple patient registries and observational cohort studies have examined the survival of different anti-TNFs in biologic-experienced (mainly anti-TNFs) patients. In these studies, the 1 year drug survival ranged widely from 51 to 77% (12,(20)(21)(22)(23)(24)(25)(26)(27). Nevertheless, real life data comparing directly anti-TNF and anti-IL17 (SEC) drug survival are missing.…”

Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany

“…According to a recently published systematic literature review [25], in 12 real-world studies comparing various TNFi treatments of immunemediated rheumatic diseases, GLM persistence was found to be significantly better than or equal to the persistence of its comparators. In conclusion, overall GLM persistence (regardless of treatment line) at 24 months approximated 50%, with a lower persistence in AS (43%) patients than in RA and PsA.…”